ArticleOncology letters2025
Leucine-rich repeat-containing G protein-coupled receptor 4 promotes proliferation, invasion and migration, and inhibits apoptosis in non-small cell lung cancer cells.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4/GPCR48) belongs to subfamily B of the GPCR superfamily. LGR4 is a transmembrane signaling molecule involved in organogenesis across multiple tissue systems and contributes to cancer progression. To the best of our knowledge, however, the specific involvement of LGR4/GPR48 in non-small cell lung cancer (NSCLC) has not been comprehensively studied. The present study aimed to elucidate the mechanisms by which LGR4 promotes the progression of NSCLC. First, the expression and survival of LGR4 were analyzed by downloading relevant data from The Cancer Genome Atlas database. Subsequently, immunohistochemistry was conducted to evaluate the association between LGR4 expression levels and prognostic outcomes in tissue samples from NSCLC. LGR4 levels were further determined across NSCLC cell line subtypes via western blotting and reverse transcription-quantitative PCR. LGR4 expression was silenced in the A549 and H226 cell lines using small interfering RNA. Flow cytometry, Cell Counting Kit-8 assays and Transwell assays were then used to study the effects on tumor cells after LGR4 knockdown. Finally, to elucidate the oncogenic mechanisms of LGR4, Gene Set Enrichment Analysis (GSEA) 4.3.3 software was utilized to identify signaling pathways potentially activated by the elevated expression of LGR4 in NSCLC tumor samples. The present findings indicated that LGR4 was significantly overexpressed in NSCLC and associated with worse clinical outcomes. Additionally, silencing LGR4 promoted apoptosis in A549 and H226 cells, while also suppressing cell proliferation, invasion and metastasis in NSCLC. Moreover, GSEA indicated that elevated expression of LGR4 in NSCLC may trigger activation of critical signaling pathways, such as the Wnt/β-catenin, TGF-β and PI3K/AKT/mTOR pathways. Therefore, LGR4 could represent a promising biomarker and a potential target for therapy in the management of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.